CDIC Cardiodynamics International (MM)

Stanford Study Finds BioZ(R) ICG Superior to Echocardiography for Pacemaker Optimization SAN DIEGO, Nov. 14 /PRNewswire-FirstCall/ -- CardioDynamics (NASDAQ: CDIC), the innovator and leader of Impedance Cardiography (ICG) technology and manufacturer of BioZ noninvasive cardiac monitoring systems, announced today two studies which correlate BioZ(R) with Ejection Fraction (EF) from echocardiography (echo). Researchers from Stanford Medical Center, Stanford, California, reported results of a pacemaker optimization study at the Twelfth Annual Heart Failure Society of America (HFSA) Scientific Meeting in Toronto, Canada. The study's purpose was to identify a method more suitable than echo for routine use in pacemaker optimization. Researchers compared ICG and echo both in terms of data quality and ease of use. The researchers concluded that the BioZ(R) ICG provided more precise optimization of pacemaker patients than echo, and ICG had the added benefit of not requiring any manual measurement or subjective interpretation. Separately, CardioDynamics announced that Congestive Heart Failure, a leading heart failure journal, published important findings last week from researchers at the University of Texas, Southwestern Medical Center, Dallas, Texas. The study evaluated the relationship between EF by echo or gated nuclear ventriculography and systolic time ratio (STR) by BioZ(R) ICG in outpatients with chronic heart failure. The researchers conducted this study because left ventricular EF can be used to assess patients with heart failure, however, frequent measurements are not cost-effective versus ICG which offers a low-cost, noninvasive alternative. There was an important inverse correlation between STR and EF which demonstrate an EF of /=0.50 showed a 93% sensitivity with an 85% specificity. STR was also able to distinguish intact, (>50%) from impaired (